Garnavou-Xirou Christina, Bontzos Georgios, Smoustopoulos Georgios, Velissaris Stavros, Papadopoulos Alexandros, Georgopoulos Efstathios, Stavrakas Panagiotis, Georgakopoulos Constantinos, Xirou Tina, Kozobolis Vasileios
Department of Ophthalmology, Korgialenio-Benakio General Hospital, Athens, Greece.
Department of Ophthalmology, University Hospital of Patras, Patras, Greece.
Maedica (Bucur). 2024 Jun;19(2):380-387. doi: 10.26574/maedica.2024.19.2.380.
Retinal vein occlusion (RVO) is a major cause of vision impairment globally. Obstruction in the retinal venous system is often due to thrombus formation at arteriovenous crossing points, leading to symptoms localized to the affected retinal area. Systemic conditions like hypertension, diabetes mellitus, dyslipidemia and heart disease are recognized risk factors for RVO, influencing the components of Virchow's triad.
This work aims to provide an updated overview of systemic risk factors associated with branch retinal vein occlusion (BRVO) development and to explore management options for the prevention or modification of associated risks.
Review of the literature concerning the pathogenesis and risk factors of BRVO, including diabetes mellitus, hyperlipidemia, hematologic conditions, hormonal factors, thyroid disease, and the impact of COVID-19 and related vaccines on BRVO incidence.
Diabetes mellitus contributes to BRVO through mechanisms like endothelial dysfunction and thrombogenesis. Hyperlipidemia - through lipid-mediated vascular changes - and hematologic conditions - by predisposing to hypercoagulability - significantly increase BRVO risk. Hormonal imbalances and thyroid diseases also influence BRVO development through their effects on vascular and hemostatic systems. Furthermore, COVID-19 has been identified as a potential risk factor for BRVO, possibly due to its pro- thrombotic effects.
Branch retinal vein occlusion represents a complex interplay of systemic and local vascular factors, necessitating comprehensive management strategies. Early detection and modification of risk factors is crucial for preventing vision impairment associated with BRVO. The ongoing pandemic and its systemic implications underscore the importance of continued review into the multifactorial etiology of BRVO and optimization of management strategies to improve patient outcomes.
视网膜静脉阻塞(RVO)是全球视力损害的主要原因。视网膜静脉系统的阻塞通常是由于动静脉交叉点处血栓形成,导致症状局限于受影响的视网膜区域。高血压、糖尿病、血脂异常和心脏病等全身性疾病是公认的RVO危险因素,影响着魏尔啸氏三要素的组成部分。
本研究旨在提供与分支视网膜静脉阻塞(BRVO)发生相关的全身性危险因素的最新概述,并探索预防或改变相关风险的管理方案。
回顾有关BRVO发病机制和危险因素的文献,包括糖尿病、高脂血症、血液学疾病、激素因素、甲状腺疾病,以及2019冠状病毒病(COVID-19)和相关疫苗对BRVO发病率的影响。
糖尿病通过内皮功能障碍和血栓形成等机制导致BRVO。高脂血症通过脂质介导的血管变化,以及血液学疾病通过易导致高凝状态,显著增加BRVO风险。激素失衡和甲状腺疾病也通过对血管和止血系统的影响影响BRVO的发生。此外,COVID-19已被确定为BRVO的潜在危险因素,可能是由于其促血栓形成作用。
分支视网膜静脉阻塞代表了全身和局部血管因素的复杂相互作用,需要综合管理策略。早期发现和改变危险因素对于预防与BRVO相关的视力损害至关重要。持续的大流行及其对全身的影响凸显了持续审查BRVO多因素病因和优化管理策略以改善患者预后的重要性。